Welcome to our dedicated page for Akari Therapeutics news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics stock.
Akari Therapeutics plc develops oncology antibody-drug conjugates built around RNA splicing modulator payloads. News about AKTX centers on its ADC platform, the PH1 payload technology, and lead program AKTX-101, a TROP2-targeted ADC studied in solid tumor models including bladder, lung and breast cancer. Updates also cover intellectual-property protection for the company’s payload chemistry and therapeutic applications.
Recurring company developments include preclinical data releases, oncology conference abstracts, strategic development collaborations, capital-structure disclosures, governance matters, and American Depositary Share program updates. As an ADR issuer, Akari’s news may also address ordinary-share and ADS mechanics tied to Nasdaq listing requirements and shareholder approvals.
Akari Therapeutics (Nasdaq: AKTX) reported new preclinical data for AKTX-101, a TROP2-targeted antibody-drug conjugate (ADC) carrying its novel PH1 RNA spliceosome-modulating payload, in urothelial cancer models representing metastatic disease and ADC-resistant tumors.
AKTX-101 showed statistically significant anti-tumor activity in the UM-UC-14 metastatic urothelial carcinoma model, where Padcev (enfortumab vedotin) had limited responsiveness, and slowed growth of tumors that had developed resistance to the first-generation TROP2 ADC Trodelvy (sacituzumab govitecan). According to Akari, these results support the potential of PH1 to address payload-specific resistance and enable differentiated ADC sequencing strategies as ADC use expands. The company is advancing IND-enabling work for AKTX-101, targeting a Phase 1 clinical trial start in mid-2027, and is pursuing additional tumor-specific programs and collaborations to broaden its PH1 payload platform.
Akari Therapeutics (Nasdaq: AKTX) reported second quarter 2026 financial results and progress on its lead ADC candidate AKTX-101. The company is conducting IND-enabling activities and remains focused on initiating a Phase 1 clinical trial in mid-2027, supported by manufacturing and development work.
Akari strengthened its balance sheet with approximately $8.6 million in gross financing during the quarter, including a $5.5 million private placement and $3.1 million from warrant exercises, resulting in about $8.0 million of net proceeds and cash of $7.7 million as of June 30, 2026.
The company entered a research collaboration with Whitehawk Therapeutics to explore dual-payload ADCs combining Akari’s PH1 spliceosome-modulating payload with Whitehawk’s topoisomerase I payload. Akari also presented preclinical data at ASCO 2026 showing synergistic anti-tumor activity of its PH1 payload with an approved KRAS inhibitor in KRAS-mutated pancreatic cancer models and expanded its international patent portfolio for the PH1 platform.
Akari Therapeutics (Nasdaq: AKTX) released a new CEO Corner in which President and CEO Abizer Gaslightwala discusses the company’s recently announced strategic research collaboration with WhiteHawk Therapeutics and its implications for antibody drug conjugate (ADC) innovation.
The discussion focuses on combining Akari’s proprietary PH1 spliceosome‑modulating payload with WhiteHawk’s differentiated TOP1 inhibitor ADC platform in a dual‑payload strategy intended to evaluate whether complementary mechanisms of action can broaden therapeutic activity and generate translational insights. According to Akari, this collaboration highlights the versatility and potential broad applicability of the PH1 platform. Mr. Gaslightwala also addresses rising industry interest in differentiated payload technologies, the role of scientifically driven partnerships in validating novel platforms, and Akari’s plan to advance AKTX‑101, its lead TROP2‑targeting ADC, toward planned Phase 1 clinical evaluation as part of a broader strategy to build a multi‑application PH1 payload franchise.
Akari Therapeutics (Nasdaq: AKTX) announced a strategic research collaboration with Whitehawk Therapeutics to evaluate combining Akari’s proprietary PH1 spliceosome-modulating payload with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC platform. The collaboration focuses on preclinical research in oncology antibody drug conjugates (ADCs).
Under the agreement, Akari will lead the design, execution and evaluation of a series of focused preclinical studies. Initial work will span multiple preclinical workstreams assessing dual-payload compatibility and potential synergies, generating data intended to inform future development decisions and potential broader collaboration between the companies. According to Akari, the program aims to further validate PH1’s differentiated mechanism and explore development of a potential first-in-class dual-payload ADC technology. Whitehawk views dual-payload approaches as a possible next opportunity to expand its ADC platform. The collaboration is expected to start immediately, with interim data updates anticipated as studies progress, and both companies will jointly review results to determine whether they support expanded development discussions.
Akari Therapeutics (Nasdaq: AKTX) appointed former AACR President and oncology drug development leader Patricia LoRusso, D.O. to its Scientific Advisory Board.
Her early-phase and experimental therapeutics expertise will support advancement of lead TROP2-targeting ADC AKTX-101, now in IND-enabling studies with a Phase 1 first-in-human trial targeted for mid-2027.
Akari Therapeutics (Nasdaq: AKTX) completed its previously announced $5.5 million PIPE by consolidating remaining tranches into a single June 26, 2026 closing. Combined with approximately $2.8 million from warrant exercises in May, Akari received about $8.3 million in Q2 2026 to support upcoming clinical and regulatory milestones.
The company plans to use this added financial flexibility to advance AKTX-101 toward a Phase 1 first-in-human trial and progress its proprietary PH1 RNA splicing modulator ADC payload, including through potential strategic partnerships.
Akari Therapeutics (Nasdaq: AKTX) released a CEO Corner discussing trends from the 2026 ASCO Meeting and its role in the evolving ADC 2.0 landscape.
Topics include KRAS-driven cancers, limitations of existing ADC payloads, Akari’s PH1 spliceosome-modulating platform, preclinical KRAS combination data, and plans for a Phase 1 trial of AKTX-101 by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) discussed the breakthrough potential of AKTX-101 and its spliceosome-modulating ADC platform in a Virtual Investor “What This Means” segment following acceptance of its first abstract at the 2026 ASCO Annual Meeting.
Management highlighted preclinical synergy with a KRAS inhibitor in KRAS-mutated pancreatic cancer models, the PH1 payload platform, and a targeted Phase 1 first-in-human trial initiation by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) reported positive preclinical data for its TROP2-targeting ADC AKTX-101 using the novel RNA spliceosome-modulating payload PH1 in KRAS-mutated pancreatic cancer models.
AKTX-101 combined with KRAS inhibitor adagrasib showed synergistic cytotoxicity in KRAS G12D and G12C cell lines, unlike comparator TROP2 ADCs with topoisomerase I payloads, which appeared antagonistic. Akari has begun IND-enabling studies and is aiming to start a Phase 1 trial by mid-2027.
Akari Therapeutics (Nasdaq: AKTX) priced a private placement expected to raise approximately $5.5 million in gross proceeds. The company will sell 1,470,588 ADSs or prefunded warrants, plus unregistered Series H, I and J warrants priced at $3.74 per ADS.
Akari plans to use net proceeds for working capital, general corporate purposes, and to advance lead ADC candidate AKTX-101 toward a first-in-human Phase 1 trial. Closings are expected in three tranches between May 27 and July 15, 2026.